GIM
SNDX icon

Granahan Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Granahan Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.77M Buy
446,988
+140,667
+46% +$2.93M 0.35% 65
2026
Q1 		$7.16M Sell
306,321
-60,472
-16% -$1.31M 0.35% 70
2025
Q4 		$7.71M Sell
366,793
-29,543
-7% -$515K 0.33% 73
2025
Q3 		$6.1M Sell
396,336
-595,052
-60% -$7.79M 0.25% 83
2025
Q2 		$9.28M Buy
991,388
+441,446
+80% +$4.86M 0.38% 69
2025
Q1 		$6.76M Sell
549,942
-355,380
-39% -$5.01M 0.34% 78
2024
Q4 		$12M Buy
905,322
+240,557
+36% +$4.12M 0.5% 59
2024
Q3 		$12.8M Buy
664,765
+70,379
+12% +$1.45M 0.5% 60
2024
Q2 		$12.2M Buy
594,386
+197,508
+50% +$4.13M 0.49% 68
2024
Q1 		$9.45M Buy
396,878
+75,967
+24% +$1.69M 0.33% 89
2023
Q4 		$6.93M Buy
+320,911
New +$4.93M 0.23% 113

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Granahan Investment Management's SNDX Position: Q2 2026 in Review

Granahan Investment Management increased its Syndax Pharmaceuticals (SNDX) stake by 46% in Q2 2026, buying an estimated $2.93M and bringing the position to 446,988 shares worth $9.77M. The position accounts for 0.35% of the portfolio, ranked #65.

Granahan Investment Management first reported a position in SNDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.8M in Q3 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Granahan Investment Management held 446,988 shares of Syndax Pharmaceuticals worth $9.77M as of Q2 2026.
  • Granahan Investment Management bought 140,667 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.93M.
  • Syndax Pharmaceuticals made up 0.35% of Granahan Investment Management's portfolio in Q2 2026, its #65 holding.
  • Granahan Investment Management first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Granahan Investment Management's Syndax Pharmaceuticals position peaked at $12.8M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.